Trials / Completed
CompletedNCT02725515
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb®5871 on Systemic Lupus Erythematosus Disease Activity
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Xencor, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the ability of XmAb5871 to maintain Systemic Lupus Erythematosus (SLE) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | XmAb5871 | |
| BIOLOGICAL | Placebo to match XmAb5871 |
Timeline
- Start date
- 2016-02-16
- Primary completion
- 2018-07-17
- Completion
- 2018-07-17
- First posted
- 2016-04-01
- Last updated
- 2019-08-20
- Results posted
- 2019-08-09
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02725515. Inclusion in this directory is not an endorsement.